about
Small nucleolar RNA signatures as biomarkers for non-small-cell lung cancerMolecular Genetics of Intracranial Meningiomas with Emphasis on Canonical Wnt SignallingReinventing diagnostics for personalized therapy in oncologyAnalysis of small nucleolar RNAs in sputum for lung cancer diagnosis.Targeted high throughput sequencing in clinical cancer settings: formaldehyde fixed-paraffin embedded (FFPE) tumor tissues, input amount and tumor heterogeneitySequencing by ligation variation with endonuclease V digestion and deoxyinosine-containing query oligonucleotides.Oncogenes and tumor suppressor genesDNA repair and personalized breast cancer therapyCharacterization of aberrant pathways across human cancersNF-κB addiction and its role in cancer: 'one size does not fit all'.Only one health, and so many omicsRNA-seq analysis of prostate cancer in the Chinese population identifies recurrent gene fusions, cancer-associated long noncoding RNAs and aberrant alternative splicings.Whole Genome Sequencing of Newly Established Pancreatic Cancer Lines Identifies Novel Somatic Mutation (c.2587G>A) in Axon Guidance Receptor Plexin A1 as Enhancer of Proliferation and Invasion.Quantification, self-renewal, and genetic tracing of FL1⁺ tumor-initiating cells in a large cohort of human gliomasThe genomics and genetics of endometrial cancer.Integrative physical oncologyInherited and acquired alterations in development of breast cancer.Restoration of the methylation status of hypermethylated gene promoters by microRNA-29b in human breast cancer: A novel epigenetic therapeutic approach.Retrotransposon-encoded reverse transcriptase in the genesis, progression and cellular plasticity of human cancer.Identification of Copy Number Aberrations in Breast Cancer Subtypes Using Persistence Topology.Small nucleolar RNAs in cancer.Genome-wide catalogue of chromosomal aberrations in barrett's esophagus and esophageal adenocarcinoma: a high-density single nucleotide polymorphism array analysis.Increasing the range of drug targets: interacting peptides provide leads for the development of oncoprotein inhibitors.Interventional radiology and the care of the oncology patient.Cancer somatic mutations disrupt functions of the EphA3 receptor tyrosine kinase through multiple mechanisms.Eagles report: Developing cancer biomarkers from genome-wide DNA methylation analyses.
P2860
Q21245710-CA30EC49-7A7A-4253-BC94-26B12F65F8C4Q26739662-F2DA34C0-5609-45CE-982A-8D37F9BB8337Q28391395-396B1585-E0D0-478C-9554-40F250A8DD2DQ30383414-DEB577FE-5433-4468-8813-2ECF1ABA1C29Q34035161-BD4B9088-17EB-4765-861F-77C2AB1DF5B9Q34094529-C8FA1D9D-257D-47EF-A24F-7D0E5684245FQ34149922-D646008F-211C-4A20-8A3F-213450DBE645Q34234936-24B8313F-009C-4279-B9B0-A2E20ADAB362Q35051387-F8D22BDB-E2C4-4131-B32C-60385BA0FC58Q35120893-E51BDE30-F9C6-401F-8005-A93EDC13B840Q35764836-02FF4597-6899-4896-AE47-97234F536A93Q35932349-C4EC88D5-9795-4850-9F04-657168EBF757Q35952075-903AFF96-BD65-481B-AD83-3D319C286A71Q36010140-AF1A51A9-DD60-4AF4-8059-4F68C9A5D7C1Q36151896-5F187267-0D98-4A97-8320-676535BC5DB5Q36754194-5C18D84A-FDE7-4E82-B605-5CAE10DEB548Q36925229-7438CEE4-FA04-40AE-AB09-22A9DE708D56Q37102684-A3FD0BF8-D174-4F5C-B7F2-39129A401002Q37129860-85B3F966-74C1-4605-B894-C3434DF8F1C2Q37200784-2E7855E2-9CED-4EAF-95ED-4F02E09162ACQ37346566-BBC798DE-1BE6-4A5A-8ED6-22BCDCE240D4Q37599640-06402060-42C3-43FC-882A-E8B58E7FF096Q38028795-5C7FB9F3-B7DA-4CCB-8A2C-9FB06220DBADQ38757170-D8017FAD-10EB-4112-8133-87266FCB66B5Q41782765-0B722826-6C43-4AED-B9D0-6D78952A11EBQ41837243-80A7C4A0-9077-4EFF-AB30-5439C93A7B19
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Our changing view of the genomic landscape of cancer.
@ast
Our changing view of the genomic landscape of cancer.
@en
type
label
Our changing view of the genomic landscape of cancer.
@ast
Our changing view of the genomic landscape of cancer.
@en
prefLabel
Our changing view of the genomic landscape of cancer.
@ast
Our changing view of the genomic landscape of cancer.
@en
P2860
P356
P1476
Our changing view of the genomic landscape of cancer.
@en
P2093
Daphne W Bell
P2860
P304
P356
10.1002/PATH.2645
P577
2010-01-01T00:00:00Z